Compares two radiotherapy schedules for the prostate in advanced prostate cancer
Tests two radiation schedules on the prostate in men with spread prostate cancer.
Plain-language title generated from the registry record
Registry title: Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer
Key facts
- Where
- Umeå, SwedenSee the site
Where in Sweden
- Cancercenter University hospital of UmeåUmeå, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Umeå University
- Trial code
- NCT04612907
- Record updated
- 28 February 2024
- Original description
de Novo metastatic prostate cancer with limited metastatic spread benefits from local radiotherapy to the prostate. Two different fractionation schedules will be tested.Read full original descriptionShow less
A Randomized Phase III, Multicenter Study to Evaluate Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer
de Novo metastatic prostate cancer with limited metastatic spread benefits from local radiotherapy to the prostate. Two different fractionation schedules will be tested.
Inclusion: Signed Informed Consent; Histological confirmed prostate cancer; Indication for early palliative radiation therapy of low burden metastatic prostate cancer. Low burden as defined by modified CHAARTED trial criteria to maximum 4 skeletal mets at any site and/or any number of lymph nodes; baseline E-PROM.
Exclusion: High burden metastatic prostate cancer including all with visceral mets; Other diseases or medication that will put the patient at risk for more toxicity from radiotherapy; Radiation treatment start later than nine months after the prostate cancer diagnosis; Unable to comply with study procedures; Severe micturition problems, IPSS > 20 ( International Prostate Symptom Score).